{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:35:15Z","timestamp":1759541715633,"version":"3.43.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,4]]},"DOI":"10.7759\/cureus.89366","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T21:07:41Z","timestamp":1754341661000},"source":"Crossref","is-referenced-by-count":1,"title":["Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Following Conversion Surgery for Esophageal Cancer: A Case Report"],"prefix":"10.7759","author":[{"given":"Hiromi","family":"Yasuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeyuki","family":"Yoshiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Ohi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Toiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION- 3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato K","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, et al.. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION- 3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019, 20:1506-17. 10.1016\/S1470-2045(19)30626-6","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki Y","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, et al.. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022, 386:449-62. 10.1056\/NEJMoa2111380","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000877","article-title":"Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases","volume":"33","author":"Ingen-Housz-Oro S","year":"2023","unstructured":"Ingen-Housz-Oro S, Milpied B, Bensaid B, et al.. Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases. Melanoma Res. 2023, 33:155-8. 10.1097\/CMR.0000000000000877","journal-title":"Melanoma Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.681997","article-title":"Case report: a case of trimethoprim\/sulfamethoxazole-triggered hypotensive shock: cytokine release syndrome related to immune checkpoint inhibitors and drug-induced hypersensitivity syndrome","volume":"11","author":"Urasaki T","year":"2021","unstructured":"Urasaki T, Ono M, Mochizuki T, et al.. Case report: a case of trimethoprim\/sulfamethoxazole-triggered hypotensive shock: cytokine release syndrome related to immune checkpoint inhibitors and drug-induced hypersensitivity syndrome. Front Oncol. 2021, 11:681997. 10.3389\/fonc.2021.681997","journal-title":"Front Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.1999.11754231","article-title":"Drug rash with eosinophilia and systemic symptoms (DRESS syndrome)","volume":"54","author":"Tas S","year":"2016","unstructured":"Tas S, Simonart T. Drug rash with eosinophilia and systemic symptoms (DRESS syndrome). Acta Clin Belg. 2016, 54:197-200. 10.1080\/17843286.1999.11754231","journal-title":"Acta Clin Belg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.597761","article-title":"The roles of immunoregulatory networks in severe drug hypersensitivity","volume":"12","author":"Hsu YO","year":"2021","unstructured":"Hsu YO, Lu KL, Fu Y, et al.. The roles of immunoregulatory networks in severe drug hypersensitivity. Front Immunol. 2021, 12:597761. 10.3389\/fimmu.2021.597761","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.11.017","article-title":"Nivolumab-associated DRESS syndrome: a case report","volume":"5","author":"Lu J","year":"2019","unstructured":"Lu J, Thuraisingam T, Chergui M, Nguyen K. Nivolumab-associated DRESS syndrome: a case report. JAAD Case Rep. 2019, 5:216-8. 10.1016\/j.jdcr.2018.11.017","journal-title":"JAAD Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002879","article-title":"Nivolumab-associated DRESS in a genetic susceptible individual","volume":"9","author":"Ai L","year":"2021","unstructured":"Ai L, Gao J, Zhao S, et al.. Nivolumab-associated DRESS in a genetic susceptible individual. J Immunother Cancer. 2021, 9:10.1136\/jitc-2021-002879","journal-title":"J Immunother Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/mrcr\/rxac061","article-title":"Azathioprine-induced hypersensitivity reaction mimicking sepsis in a patient with systemic lupus erythematosus","volume":"7","author":"McKenzie PL","year":"2023","unstructured":"McKenzie PL, Chao Y, Pathak S, Kazi S. Azathioprine-induced hypersensitivity reaction mimicking sepsis in a patient with systemic lupus erythematosus. Mod Rheumatol Case Rep. 2023, 7:74-7. 10.1093\/mrcr\/rxac061","journal-title":"Mod Rheumatol Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000487670","article-title":"C-reactive protein and procalcitonin in case reports of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"176","author":"H\u00fcbner ST","year":"2018","unstructured":"H\u00fcbner ST, Bertoli R, R\u00e4tz Bravo AE, et al.. C-reactive protein and procalcitonin in case reports of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Int Arch Allergy Immunol. 2018, 176:44-54. 10.1159\/000487670","journal-title":"Int Arch Allergy Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2025.03.007","article-title":"Recent advances in the diagnosis and treatment of DIHS\/DRESS in 2025","volume":"74","author":"Mizukawa Y","year":"2025","unstructured":"Mizukawa Y, Shiohara T. Recent advances in the diagnosis and treatment of DIHS\/DRESS in 2025. Allergol Int. 2025, 74:372-9. 10.1016\/j.alit.2025.03.007","journal-title":"Allergol Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/392551-drug-reaction-with-eosinophilia-and-systemic-symptoms-dress-following-conversion-surgery-for-esophageal-cancer-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T21:07:42Z","timestamp":1754341662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/392551-drug-reaction-with-eosinophilia-and-systemic-symptoms-dress-following-conversion-surgery-for-esophageal-cancer-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.89366","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,8,4]]}}}